Cargando…
COVID-19 treatments, QT interval, and arrhythmic risk: The need for an international registry on arrhythmias
Autores principales: | Crotti, Lia, Arbelo, Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Heart Rhythm Society.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7248630/ https://www.ncbi.nlm.nih.gov/pubmed/32470627 http://dx.doi.org/10.1016/j.hrthm.2020.05.024 |
Ejemplares similares
-
QT interval and arrhythmic safety of hydroxychloroquine monotherapy in coronavirus disease 2019
por: Sridhar, Arun R., et al.
Publicado: (2020) -
Arrhythmic profile and 24-hour QT interval variability in COVID-19 patients treated with hydroxychloroquine and azithromycin
por: Cipriani, Alberto, et al.
Publicado: (2020) -
Effect of Triple Combination Therapy With Lopinavir-Ritonavir, Azithromycin, and Hydroxychloroquine on QT Interval and Arrhythmic Risk in Hospitalized COVID-19 Patients
por: Russo, Vincenzo, et al.
Publicado: (2020) -
Echocardiography-Guided Arrhythmic Risk Prediction in the Long QT Syndrome
por: Agarwal, Rakesh, et al.
Publicado: (2021) -
Adrenal insufficiency causes life-threatening arrhythmia with prolongation of QT interval
por: Komuro, Jin, et al.
Publicado: (2015)